Abstract Ceftolozane/tazobactam (C/T) has emerged as a potential agent for the treatment of
extensively drug-resistant (XDR) Pseudomonas aeruginosa infections. As it is a time …

Background. Empirical combination therapy is recommended for patients with known or
suspected Pseudomonas aeruginosa (PA) infection as a means to decrease the likelihood …

Background The optimal antibiotic regimen for Pseudomonas aeruginosa bacteremia is
controversial. Although β-lactam monotherapy is common, data to guide the choice between …

This study evaluated the pharmacodynamics of continuous infusion β-lactams against
pulmonary isolates of Gram-negative bacteria from patients managed in intensive care units …

Background Critically ill patients display altered pharmacokinetics and pharmacodynamics
and are more likely to be infected with more resistant pathogens. Beta-lactam antibiotics …

Background The optimal duration of antimicrobial therapy for uncomplicated Pseudomonas
aeruginosa bloodstream infection (BSI) is unknown. We compared the outcomes of short …

Optimizing antibiotic combinations is promising to combat multidrug-resistant Pseudomonas
aeruginosa. This study aimed to systematically evaluate synergistic bacterial killing and …

It is unknown as to whether other beta-lactams can be used for bloodstream infections (BSI)
resulting from Pseudomonas aeruginosa (PA) which are non-susceptible to one or more …

OBJECTIVES: Beta-lactam antibiotics exhibit high interindividual variability in drug
concentrations in patients with critical illness which led to an interest in the use of …

Pseudomonas aeruginosa bacteremia is an infection associated with a high mortality rate.
Piperacillin-tazobactam is a β-lactam–β-lactamase inhibitor combination that is frequently …